The impact of intravitreal dexamethasone implant (Ozurdex®) on retrobulbar hemodynamics in patients with diabetic macular edema and retinal vein occlusions

2019 ◽  
Vol 38 (3) ◽  
pp. 240-248
Author(s):  
Mustafa Gok ◽  
Hilal Altas ◽  
Hasan Burhanettin Kapti
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
The Impact ◽  
Retinal Vein Occlusions ◽  
Retrobulbar Hemodynamics

Long-Term Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Diabetic Macular Edema

2016 ◽  
Vol 26 (5) ◽  
pp. 454-459 ◽  
Author(s):  
Frederic Matonti ◽  
Stephan Pommier ◽  
Franck Meyer ◽  
Christian Hajjar ◽  
Pierre Yves Merite ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone

Efficacy and safety of intravitreal dexamethasone implant in treatment naïve eyes with diabetic macular edema: Real world experience

2020 ◽  
pp. 112067212094976
Author(s):  
Dhanashree Ratra ◽  
Unnati Sharma ◽  
Daleena Dalan
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Efficacy And Safety ◽  
Visual Improvement ◽  
Intravitreal Dexamethasone Implant ◽  
Treatment Naïve ◽  
Intravitreal Dexamethasone ◽  
Macular Ischemia

Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant in treatment naïve eyes with diabetic macular edema (DME). Methods: A retrospective analysis of treatment naïve eyes with DME which received intravitreal dexamethasone implant between January 2016 and March 2018 was done. Demographic details of the patients, ocular examination findings at baseline and on follow up visits were noted. Morphological features of DME and central macular thickness were noted on optical coherence tomography at each visit. The details regarding additional treatment for macular edema on follow up were noted. Results: Sixty five eyes were included in the study. The mean age was 59.14 ± 9.59 years. The follow up ranged from 6 to 48 months. Psuedophakic eyes showed visual improvement whereas the phakic eyes showed stable vision. The central foveal thickness showed significant reduction ( p = 0.05) in all the eyes. The best corrected visual acuity at final follow up (+0.65 logMAR) was slightly less as compared to baseline (+0.62 logMAR). Retreatment was needed in 37% eyes and antiglaucoma medications in 8% eyes. Cataract progression was noted in 24 eyes (37%); 17 eyes (26.1%) underwent surgery. Notably, 27 eyes (41.5%) had some degree of macular ischemia at baseline. And five eyes (7.7%) showed progression of retinopathy leading to vitreous hemorrhage. Conclusion: Dexamethasone implant is helpful in reducing the macular thickness and stabilizing the vision in treatment naïve DME; requiring less number of treatment sessions. However, it does not prevent progression of diabetic retinopathy. The visual improvement may be affected by cataract and macular ischemia.

Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema

2019 ◽  
Vol 27 (8) ◽  
pp. 1203-1210 ◽  
Author(s):  
Marc Figueras-Roca ◽  
Anna Sala-Puigdollers ◽  
Socorro Alforja ◽  
Josep Torras ◽  
Jorge Peraza-Nieves ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Aqueous Humour ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone
Sign in / Sign up

Export Citation Format

Share Document